-
1
-
-
75149170979
-
Fibroblast growth factor signalling: From development to cancer
-
Turner N and Grose R (2010). Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10(2), 116-129.
-
(2010)
Nat Rev Cancer
, vol.10
, Issue.2
, pp. 116-129
-
-
Turner, N.1
Grose, R.2
-
2
-
-
79959713140
-
Fibroblast growth factors and their receptors in cancer
-
Wesche J, Haglund K, and Haglund EM (2011). Fibroblast growth factors and their receptors in cancer. Biochem J 437(2), 199-213.
-
(2011)
Biochem J
, vol.437
, Issue.2
, pp. 199-213
-
-
Wesche, J.1
Haglund, K.2
Haglund, E.M.3
-
3
-
-
84859415553
-
Molecular pathways: Fibroblast growth factor signaling: A new therapeutic opportunity in cancer
-
Brooks AN, Kilgour E, and Smith PD (2012). Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 18(7), 1855-1862.
-
(2012)
Clin Cancer Res
, vol.18
, Issue.7
, pp. 1855-1862
-
-
Brooks, A.N.1
Kilgour, E.2
Smith, P.D.3
-
4
-
-
60549084927
-
Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A novel class of receptor tyrosine kinase inhibitors
-
Renhowe PA, Pecchi S, Shafer CM, Machajewski TD, Jazan EM, Taylor C, Antonios-McCrea W, McBride CM, Frazier K, Wiesmann M, et al. (2009). Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. J Med Chem 52(2), 278-292.
-
(2009)
J Med Chem
, vol.52
, Issue.2
, pp. 278-292
-
-
Renhowe, P.A.1
Pecchi, S.2
Shafer, C.M.3
McHajewski, T.D.4
Jazan, E.M.5
Taylor, C.6
Antonios-McCrea, W.7
McBride, C.M.8
Frazier, K.9
Wiesmann, M.10
-
5
-
-
84857357820
-
Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma
-
Huynh H, Chow PK, TaiWM, Choo SP, Chung AY, Ong HS, Soo KC, Ong R, Linnartz R., and Shi MM (2012). Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol 56(3), 595-601.
-
(2012)
J Hepatol
, vol.56
, Issue.3
, pp. 595-601
-
-
Huynh, H.1
Chow, P.K.2
Tai, W.M.3
Choo, S.P.4
Chung, A.Y.5
Ong, H.S.6
Soo, K.C.7
Ong, R.8
Linnartz, R.9
Shi, M.M.10
-
6
-
-
84862145477
-
A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma
-
Sivanand S, Pena-Llopis S, Zhao H, Kucejova B, Spence P, Pavia-Jimenez A, Yamasaki T., McBride DJ, Gillen J, Wolff NC, et al. (2012). A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med 4(137), 137ra75.
-
(2012)
Sci Transl Med
, vol.4
, Issue.137
-
-
Sivanand, S.1
Pena-Llopis, S.2
Zhao, H.3
Kucejova, B.4
Spence, P.5
Pavia-Jimenez, A.6
Yamasaki, T.7
McBride, D.J.8
Gillen, J.9
Wolff, N.C.10
-
7
-
-
77952828838
-
Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis
-
Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, and Hynes NE (2010). Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 70(10), 4151-4162.
-
(2010)
Cancer Res
, vol.70
, Issue.10
, pp. 4151-4162
-
-
Dey, J.H.1
Bianchi, F.2
Voshol, J.3
Bonenfant, D.4
Oakeley, E.J.5
Hynes, N.E.6
-
8
-
-
81055124256
-
Targeting FGFR/PDGFR/ VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer
-
Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler E. K, Stoeltzing O, and Lang SA (2011). Targeting FGFR/PDGFR/ VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther 10(11), 2157-2167.
-
(2011)
Mol Cancer Ther
, vol.10
, Issue.11
, pp. 2157-2167
-
-
Taeger, J.1
Moser, C.2
Hellerbrand, C.3
Mycielska, M.E.4
Glockzin, G.5
Schlitt, H.J.6
Geissler, E.K.7
Stoeltzing, O.8
Lang, S.A.9
-
9
-
-
15944378835
-
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
-
Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, and Stewart AK (2005). CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105(7), 2941-2948.
-
(2005)
Blood
, vol.105
, Issue.7
, pp. 2941-2948
-
-
Trudel, S.1
Li, Z.H.2
Wei, E.3
Wiesmann, M.4
Chang, H.5
Chen, C.6
Reece, D.7
Heise, C.8
Stewart, A.K.9
-
10
-
-
22344453138
-
CHIR-258: A potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia
-
Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, Tang Y., Shephard L, Goldbeck C, Oei Y, et al. (2005). CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res 11(14), 5281-5291.
-
(2005)
Clin Cancer Res
, vol.11
, Issue.14
, pp. 5281-5291
-
-
de Lopes Menezes, D.E.1
Peng, J.2
Garrett, E.N.3
Louie, S.G.4
Lee, S.H.5
Wiesmann, M.6
Tang, Y.7
Shephard, L.8
Goldbeck, C.9
Oei, Y.10
-
11
-
-
33748349241
-
CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice
-
Xin X, Abrams TJ, Hollenbach PW, Rendahl KG, Tang Y, Oei YA, Embry MG, Swinarski D. E, Garrett EN, Pryer NK, et al. (2006). CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res 12(16), 4908-4915.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.16
, pp. 4908-4915
-
-
Xin, X.1
Abrams, T.J.2
Hollenbach, P.W.3
Rendahl, K.G.4
Tang, Y.5
Oei, Y.A.6
Embry, M.G.7
Swinarski, D.E.8
Garrett, E.N.9
Pryer, N.K.10
-
12
-
-
36348943566
-
Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome
-
Chase A, Grand FH, and Cross NC (2007). Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 110(10), 3729-3734.
-
(2007)
Blood
, vol.110
, Issue.10
, pp. 3729-3734
-
-
Chase, A.1
Grand, F.H.2
Cross, N.C.3
-
13
-
-
78650875209
-
Small molecule FGF receptor inhibitors block FGFRdependent urothelial carcinoma growth in vitro and in vivo
-
Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, and Knowles M. A (2011). Small molecule FGF receptor inhibitors block FGFRdependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 104(1), 75-82.
-
(2011)
Br J Cancer
, vol.104
, Issue.1
, pp. 75-82
-
-
Lamont, F.R.1
Tomlinson, D.C.2
Cooper, P.A.3
Shnyder, S.D.4
Chester, J.D.5
Knowles, M.A.6
-
14
-
-
84862777035
-
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
-
Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, et al. (2012). A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61(5), 673-684.
-
(2012)
Gut
, vol.61
, Issue.5
, pp. 673-684
-
-
Deng, N.1
Goh, L.K.2
Wang, H.3
Das, K.4
Tao, J.5
Tan, I.B.6
Zhang, S.7
Lee, M.8
Wu, J.9
Lim, K.H.10
-
15
-
-
42249087301
-
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors
-
Sarker D, Molife R, Evans TR, Hardie M, Marriott C, Butzberger-Zimmerli P, Morrison R., Fox JA, Heise C, Louie S, et al. (2008). A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 14(7), 2075-2081.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.7
, pp. 2075-2081
-
-
Sarker, D.1
Molife, R.2
Evans, T.R.3
Hardie, M.4
Marriott, C.5
Butzberger-Zimmerli, P.6
Morrison, R.7
Fox, J.A.8
Heise, C.9
Louie, S.10
-
16
-
-
0036566540
-
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
-
Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch K. P, and Hughes TP (2002). High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99(9), 3472-3475.
-
(2002)
Blood
, vol.99
, Issue.9
, pp. 3472-3475
-
-
Branford, S.1
Rudzki, Z.2
Walsh, S.3
Grigg, A.4
Arthur, C.5
Taylor, K.6
Herrmann, R.7
Lynch, K.P.8
Hughes, T.P.9
-
18
-
-
49649127657
-
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
-
Engelman JA and Janne PA (2008). Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14(10), 2895-2899.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.10
, pp. 2895-2899
-
-
Engelman, J.A.1
Janne, P.A.2
-
19
-
-
40049099220
-
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
-
Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M., and Eck MJ (2008). The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105(6), 2070-2075.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, Issue.6
, pp. 2070-2075
-
-
Yun, C.H.1
Mengwasser, K.E.2
Toms, A.V.3
Woo, M.S.4
Greulich, H.5
Wong, K.K.6
Meyerson, M.7
Eck, M.J.8
-
20
-
-
33750302365
-
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib
-
Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H., and Mitsudomi T (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12(19), 5764-5769.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.19
, pp. 5764-5769
-
-
Kosaka, T.1
Yatabe, Y.2
Endoh, H.3
Yoshida, K.4
Hida, T.5
Tsuboi, M.6
Tada, H.7
Kuwano, H.8
Mitsudomi, T.9
-
21
-
-
84855503769
-
The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm
-
Gibbons DL, Pricl S, Kantarjian H, Cortes J, and Quintas-Cardama A (2012). The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer 118(2), 293-299.
-
(2012)
Cancer
, vol.118
, Issue.2
, pp. 293-299
-
-
Gibbons, D.L.1
Pricl, S.2
Kantarjian, H.3
Cortes, J.4
Quintas-Cardama, A.5
-
22
-
-
53549104402
-
Activation of tyrosine kinases by mutation of the gatekeeper threonine
-
Azam M, Seeliger MA, Gray NS, Kuriyan J, and Daley GQ (2008). Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 15(10), 1109-1118.
-
(2008)
Nat Struct Mol Biol
, vol.15
, Issue.10
, pp. 1109-1118
-
-
Azam, M.1
Seeliger, M.A.2
Gray, N.S.3
Kuriyan, J.4
Daley, G.Q.5
-
23
-
-
77953218598
-
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: A 'head-to-head comparison'
-
Rosti G, Castagnetti F, Gugliotta G, Palandri F, Martinelli G, and Baccarani M (2010). Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'. Leuk Lymphoma 51(4), 583-591.
-
(2010)
Leuk Lymphoma
, vol.51
, Issue.4
, pp. 583-591
-
-
Rosti, G.1
Castagnetti, F.2
Gugliotta, G.3
Palandri, F.4
Martinelli, G.5
Baccarani, M.6
-
24
-
-
2642558897
-
Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors
-
Blencke S, Zech B, Engkvist O, Greff Z, Orfi L, Horvath Z, Keri G, Ullrich A, and Daub H (2004). Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol 11(5), 691-701.
-
(2004)
Chem Biol
, vol.11
, Issue.5
, pp. 691-701
-
-
Blencke, S.1
Zech, B.2
Engkvist, O.3
Greff, Z.4
Orfi, L.5
Horvath, Z.6
Keri, G.7
Ullrich, A.8
Daub, H.9
-
25
-
-
25444460629
-
A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: Implications for clinical resistance in targeted cancer treatment
-
von Bubnoff N, Barwisch S, Speicher MR, Peschel C, and Duyster J (2005). A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment. Cell Cycle 4(3), 400-406.
-
(2005)
Cell Cycle
, vol.4
, Issue.3
, pp. 400-406
-
-
von Bubnoff, N.1
Barwisch, S.2
Speicher, M.R.3
Peschel, C.4
Duyster, J.5
-
26
-
-
33845360035
-
Ba/F3 cells and their use in kinase drug discovery
-
Warmuth M, Kim S, Gu XJ, Xia G, and Adrian F (2007). Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol 19(1), 55-60.
-
(2007)
Curr Opin Oncol
, vol.19
, Issue.1
, pp. 55-60
-
-
Warmuth, M.1
Kim, S.2
Gu, X.J.3
Xia, G.4
Adrian, F.5
-
27
-
-
20844448211
-
A cellbased screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor
-
von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sanger J, Seipel P, Bornmann W. G, Peschel C, Clarkson B, and Duyster J (2005). A cellbased screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 105(4), 1652-1659.
-
(2005)
Blood
, vol.105
, Issue.4
, pp. 1652-1659
-
-
von Bubnoff, N.1
Veach, D.R.2
van der Kuip, H.3
Aulitzky, W.E.4
Sanger, J.5
Seipel, P.6
Bornmann, W.G.7
Peschel, C.8
Clarkson, B.9
Duyster, J.10
-
28
-
-
66149152278
-
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro
-
von Bubnoff N, Engh RA, Aberg E, Sanger J, Peschel C, and Duyster J (2009). FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 69(7), 3032-3041.
-
(2009)
Cancer Res
, vol.69
, Issue.7
, pp. 3032-3041
-
-
von Bubnoff, N.1
Engh, R.A.2
Aberg, E.3
Sanger, J.4
Peschel, C.5
Duyster, J.6
-
29
-
-
79952004905
-
The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro
-
von Bubnoff N, Gorantla SP, Engh RA, Oliveira TM, Thone S, Aberg E, Peschel C., and Duyster J (2011). The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro. Oncogene 30(8), 933-943.
-
(2011)
Oncogene
, vol.30
, Issue.8
, pp. 933-943
-
-
von Bubnoff, N.1
Gorantla, S.P.2
Engh, R.A.3
Oliveira, T.M.4
Thone, S.5
Aberg, E.6
Peschel, C.7
Duyster, J.8
-
30
-
-
79960967335
-
A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients
-
Tiedt R, Degenkolbe E, Furet P, Appleton BA, Wagner S, Schoepfer J, Buck E, Ruddy D. A, Monahan JE, Jones MD, et al. (2011). A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. Cancer Res 71(15), 5255-5264.
-
(2011)
Cancer Res
, vol.71
, Issue.15
, pp. 5255-5264
-
-
Tiedt, R.1
Degenkolbe, E.2
Furet, P.3
Appleton, B.A.4
Wagner, S.5
Schoepfer, J.6
Buck, E.7
Ruddy, D.A.8
Monahan, J.E.9
Jones, M.D.10
-
31
-
-
54049122600
-
Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations
-
Avizienyte E, Ward RA, and Garner AP (2008). Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations. Biochem J 415(2), 197-206.
-
(2008)
Biochem J
, vol.415
, Issue.2
, pp. 197-206
-
-
Avizienyte, E.1
Ward, R.A.2
Garner, A.P.3
-
32
-
-
84859643082
-
Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms
-
Deshpande A, Reddy MM, Schade GO, Ray A, Chowdary TK, Griffin JD, and Sattler M (2012). Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 26(4), 708-715.
-
(2012)
Leukemia
, vol.26
, Issue.4
, pp. 708-715
-
-
Deshpande, A.1
Reddy, M.M.2
Schade, G.O.3
Ray, A.4
Chowdary, T.K.5
Griffin, J.D.6
Sattler, M.7
-
33
-
-
23944476156
-
PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib
-
Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, and Heinrich MC (2005). PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23(23), 5357-5364.
-
(2005)
J Clin Oncol
, vol.23
, Issue.23
, pp. 5357-5364
-
-
Corless, C.L.1
Schroeder, A.2
Griffith, D.3
Town, A.4
McGreevey, L.5
Harrell, P.6
Shiraga, S.7
Bainbridge, T.8
Morich, J.9
Heinrich, M.C.10
-
34
-
-
77949277517
-
FGFR2 mutations are rare across histologic subtypes of ovarian cancer
-
Byron SA, Gartside MG, Wellens CL, Goodfellow PJ, Birrer MJ, Campbell IG, and Pollock PM (2010). FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecol Oncol 117(1), 125-129.
-
(2010)
Gynecol Oncol
, vol.117
, Issue.1
, pp. 125-129
-
-
Byron, S.A.1
Gartside, M.G.2
Wellens, C.L.3
Goodfellow, P.J.4
Birrer, M.J.5
Campbell, I.G.6
Pollock, P.M.7
-
35
-
-
58749107496
-
Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma
-
Gartside MG, Chen H, Ibrahimi OA, Byron SA, Curtis AV, Wellens CL, Bengston A., Yudt LM, Eliseenkova AV, Ma J, et al. (2009). Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res 7(1), 41-54.
-
(2009)
Mol Cancer Res
, vol.7
, Issue.1
, pp. 41-54
-
-
Gartside, M.G.1
Chen, H.2
Ibrahimi, O.A.3
Byron, S.A.4
Curtis, A.V.5
Wellens, C.L.6
Bengston, A.7
Yudt, L.M.8
Eliseenkova, A.V.9
Ma, J.10
-
36
-
-
34548250374
-
A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases
-
Chen H, Ma J, Li W, Eliseenkova AV, Xu C, Neubert TA, Miller WT, and Mohammadi M (2007). A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell 27(5), 717-730.
-
(2007)
Mol Cell
, vol.27
, Issue.5
, pp. 717-730
-
-
Chen, H.1
Ma, J.2
Li, W.3
Eliseenkova, A.V.4
Xu, C.5
Neubert, T.A.6
Miller, W.T.7
Mohammadi, M.8
-
37
-
-
33646198996
-
4-(Aminoalkylamino)-3-benzimidazolequinolinones as potent CHK-1 inhibitors
-
Ni ZJ, Barsanti P, Brammeier N, Diebes A, Poon DJ, Ng S, Pecchi S, Pfister K, Renhowe P. A, Ramurthy S, et al. (2006). 4-(Aminoalkylamino)-3-benzimidazolequinolinones as potent CHK-1 inhibitors. Bioorg Med Chem Lett 16(12), 3121-3124.
-
(2006)
Bioorg Med Chem Lett
, vol.16
, Issue.12
, pp. 3121-3124
-
-
Ni, Z.J.1
Barsanti, P.2
Brammeier, N.3
Diebes, A.4
Poon, D.J.5
Ng, S.6
Pecchi, S.7
Pfister, K.8
Renhowe, P.A.9
Ramurthy, S.10
-
38
-
-
78650159009
-
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): Lessons for overcoming kinase inhibitor resistance
-
Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J, Xu Q, Rivera V. M, Shakespeare WC, Clackson T, et al. (2011). Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77(1), 1-11.
-
(2011)
Chem Biol Drug Des
, vol.77
, Issue.1
, pp. 1-11
-
-
Zhou, T.1
Commodore, L.2
Huang, W.S.3
Wang, Y.4
Thomas, M.5
Keats, J.6
Xu, Q.7
Rivera, V.M.8
Shakespeare, W.C.9
Clackson, T.10
-
39
-
-
84889120137
-
Improved methods for building protein models in electron density maps and the location of errors in these models
-
Jones TA, Zou JY, Cowan SW, and Kjeldgaard M (1991). Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47(pt 2), 110-119.
-
(1991)
Acta Crystallogr A
, vol.47
, Issue.PART 2
, pp. 110-119
-
-
Jones, T.A.1
Zou, J.Y.2
Cowan, S.W.3
Kjeldgaard, M.4
-
40
-
-
84893482610
-
A solution for the best rotation to relate two sets of vectors
-
Kabsch W (1976). A solution for the best rotation to relate two sets of vectors. Acta Crystallogr Sect A 32, 922-923.
-
(1976)
Acta Crystallogr Sect A
, vol.32
, pp. 922-923
-
-
Kabsch, W.1
-
41
-
-
0028103275
-
The CCP4 suite: Programs for protein crystallography
-
Collaborative Computational Project, Number 4
-
Collaborative Computational Project, Number 4 (1994). The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50(pt 5), 760-763.
-
(1994)
Acta Crystallogr D Biol Crystallogr
, vol.50
, Issue.PART 5
, pp. 760-763
-
-
-
43
-
-
58149399336
-
A crystallographic snapshot of tyrosine trans-phosphorylation in action
-
Chen H, Xu CF, Ma J, Eliseenkova AV, Li W, Pollock PM, Pitteloud N, Miller WT, Neubert TA, and Mohammadi M (2008). A crystallographic snapshot of tyrosine trans-phosphorylation in action. Proc Natl Acad Sci USA 105(50), 19660-19665.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, Issue.50
, pp. 19660-19665
-
-
Chen, H.1
Xu, C.F.2
Ma, J.3
Eliseenkova, A.V.4
Li, W.5
Pollock, P.M.6
Pitteloud, N.7
Miller, W.T.8
Neubert, T.A.9
Mohammadi, M.10
-
44
-
-
5444250989
-
Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities
-
Ibrahimi OA, Zhang F, Eliseenkova AV, Itoh N, Linhardt RJ, and Mohammadi M (2004). Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet 13(19), 2313-2324.
-
(2004)
Hum Mol Genet
, vol.13
, Issue.19
, pp. 2313-2324
-
-
Ibrahimi, O.A.1
Zhang, F.2
Eliseenkova, A.V.3
Itoh, N.4
Linhardt, R.J.5
Mohammadi, M.6
-
45
-
-
84857549430
-
FGFR2 point mutations in 466 endometrioid endometrial tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features
-
Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, Goodfellow PJ, and Pollock PM (2012). FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One 7(2), e30801.
-
(2012)
PLoS One
, vol.7
, Issue.2
-
-
Byron, S.A.1
Gartside, M.2
Powell, M.A.3
Wellens, C.L.4
Gao, F.5
Mutch, D.G.6
Goodfellow, P.J.7
Pollock, P.M.8
-
46
-
-
0038607097
-
The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum
-
Lievens PM and Liboi E (2003). The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. J Biol Chem 278(19), 17344-17349.
-
(2003)
J Biol Chem
, vol.278
, Issue.19
, pp. 17344-17349
-
-
Lievens, P.M.1
Liboi, E.2
-
47
-
-
5644241730
-
The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling
-
Lievens PM, Mutinelli C, Baynes D, and Liboi E (2004). The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling. J Biol Chem 279(41), 43254-43260.
-
(2004)
J Biol Chem
, vol.279
, Issue.41
, pp. 43254-43260
-
-
Lievens, P.M.1
Mutinelli, C.2
Baynes, D.3
Liboi, E.4
-
48
-
-
47249122523
-
Drug-sensitive FGFR2 mutations in endometrial carcinoma
-
Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W., Grewal R, Hanna M, et al. (2008). Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 105(25), 8713-8717.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, Issue.25
, pp. 8713-8717
-
-
Dutt, A.1
Salvesen, H.B.2
Chen, T.H.3
Ramos, A.H.4
Onofrio, R.C.5
Hatton, C.6
Nicoletti, R.7
Winckler, W.8
Grewal, R.9
Hanna, M.10
-
49
-
-
52049086201
-
Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation
-
Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA, Goodfellow P. J, and Pollock PM (2008). Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res 68(17), 6902-6907.
-
(2008)
Cancer Res
, vol.68
, Issue.17
, pp. 6902-6907
-
-
Byron, S.A.1
Gartside, M.G.2
Wellens, C.L.3
Mallon, M.A.4
Keenan, J.B.5
Powell, M.A.6
Goodfellow, P.J.7
Pollock, P.M.8
-
50
-
-
84859402751
-
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFRamplified or mutated cancer models
-
Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Clackson T, and Rivera VM (2012). Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFRamplified or mutated cancer models. Mol Cancer Ther 11(3), 690-699.
-
(2012)
Mol Cancer Ther
, vol.11
, Issue.3
, pp. 690-699
-
-
Gozgit, J.M.1
Wong, M.J.2
Moran, L.3
Wardwell, S.4
Mohemmad, Q.K.5
Narasimhan, N.I.6
Shakespeare, W.C.7
Wang, F.8
Clackson, T.9
Rivera, V.M.10
-
51
-
-
30144432781
-
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
-
Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH, Brandts C., Serve H, Roesel J, Giles F, et al. (2006). Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 107(1), 293-300.
-
(2006)
Blood
, vol.107
, Issue.1
, pp. 293-300
-
-
Heidel, F.1
Solem, F.K.2
Breitenbuecher, F.3
Lipka, D.B.4
Kasper, S.5
Thiede, M.H.6
Brandts, C.7
Serve, H.8
Roesel, J.9
Giles, F.10
-
52
-
-
34250829395
-
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes
-
Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, Mohammadi M., Futreal PA, Stratton MR, Trent JM, et al. (2007). Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26, 7158-7162.
-
(2007)
Oncogene
, vol.26
, pp. 7158-7162
-
-
Pollock, P.M.1
Gartside, M.G.2
Dejeza, L.C.3
Powell, M.A.4
Mallon, M.A.5
Davies, H.6
Mohammadi, M.7
Futreal, P.A.8
Stratton, M.R.9
Trent, J.M.10
-
53
-
-
79957949444
-
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study
-
Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, Rotmensch J., Barnes MN, Hanjani P, and Leslie KK (2011). Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 29(16), 2259-2265.
-
(2011)
J Clin Oncol
, vol.29
, Issue.16
, pp. 2259-2265
-
-
Aghajanian, C.1
Sill, M.W.2
Darcy, K.M.3
Greer, B.4
McMeekin, D.S.5
Rose, P.G.6
Rotmensch, J.7
Barnes, M.N.8
Hanjani, P.9
Leslie, K.K.10
-
54
-
-
84881048300
-
Preclinical efficacy of FP-1039 (FGFR1:Fc) in endometrial carcinoma models with activating mutations in FGFR2
-
American Association for Cancer Research, Washington, DC
-
Harding TC, Palencia S, Long L, Finer JT, Keer HN, Baker KP, and Kavanaugh WM (2010). Preclinical efficacy of FP-1039 (FGFR1:Fc) in endometrial carcinoma models with activating mutations in FGFR2. In American Association for Cancer Research (AACR) 101st Annual Meeting 2010. American Association for Cancer Research, Washington, DC.
-
(2010)
American Association for Cancer Research (AACR) 101st Annual Meeting 2010
-
-
Harding, T.C.1
Palencia, S.2
Long, L.3
Finer, J.T.4
Keer, H.N.5
Baker, K.P.6
Kavanaugh, W.M.7
|